TECHNETIUM TC 99M TILMANOCEPT
drugOn this page
Also known as LymphoseekLymphoseek kitTechnetium (99mtc) tilmanoceptTechnetium tc-99m tilmanocept
Summary
Technetium Tc 99M Tilmanocept (CHEMBL2108726) is an approved protein (ATC V09IA09); indicated across 8 conditions including squamous cell carcinoma and breast neoplasm.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Protein
- ATC class: V09IA09
- Indications: 8 conditions
- Clinical trials: 10
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108726 |
| Name | TECHNETIUM TC 99M TILMANOCEPT |
| Type | Protein |
| Max phase | 4 |
| ATC | V09IA09 |
Also known as: Lymphoseek, Lymphoseek kit, Technetium (99mtc) tilmanocept, Technetium tc 99m tilmanocept, Technetium tc-99m tilmanocept, TECHNETIUM TC 99M TILMANOCEPT
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
8 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| squamous cell carcinoma | 4 | MONDO:0005096 | EFO:0000707 |
| breast neoplasm | 4 | MONDO:0021100 | MONDO:0007254 |
| epilepsy | 3 | MONDO:0005027 | EFO:0000474 |
| endometrium neoplasm | 3 | MONDO:0021251 | MONDO:0011962 |
| rheumatoid arthritis | 2 | MONDO:0008383 | EFO:0000685 |
| central nervous system neoplasm | 1 | MONDO:0006130 | EFO:1000158 |
| melanoma | 0 | MONDO:0005105 | EFO:0000756 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 10.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 4 |
| PHASE3 | 3 |
| PHASE4 | 2 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02287675 | PHASE4 | COMPLETED | Sentinel Lymph Node Biopsy Findings in Patients With Breast Cancer |
| NCT04261179 | PHASE4 | UNKNOWN | Study Comparing Lymphoseek® vs. Albumin Nanocolloid in Head and Neck, Melanoma and Breast Cancer |
| NCT00671918 | PHASE3 | COMPLETED | Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma |
| NCT00911326 | PHASE3 | TERMINATED | Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma |
| NCT01106040 | PHASE3 | COMPLETED | Breast and Melanoma Trial With Lymphoseek to Identify Lymph Nodes |
| NCT01902953 | PHASE2 | COMPLETED | Lymphoseek® as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC) |
| NCT02857608 | PHASE2 | WITHDRAWN | A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the Anus |
| NCT03405142 | PHASE2 | COMPLETED | Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer |
| NCT04511026 | PHASE2 | TERMINATED | Concurrent Use Lymphoseek & Indocyanine Green in Sentinel Lymph Node Detection in Endometrial Cancer |
| NCT02517775 | Not specified | COMPLETED | Effects of Cranberry Consumption in Vascular Function in Healthy Individuals |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).